• PMH34- COMPARISON OF OLANZAPINE VERSUS QUETIAPINE IN THE TREATMENT OF HOSPITALIZED PATIENTS WITH SCHIZOPHRENIA

    May 1, 2003, 00:00

  • QL3- DIABETIC PATIENTSWILLINGNESS TO PAY FOR DIABETES EDUCATION BY PHARMACISTS- VALIDITY OF CONTINGENT VALUATION METHOD

    May 1, 2003, 00:00

  • CV7- COST-EFFECTIVENESS OF CLOPIDOGREL IN PATIENTS WITH ISCHEMIC STROKE, MYOCARDIAL INFARCTION, OR PERIPHERAL ARTERIAL DISEASE

    May 1, 2003, 00:00

  • PAR I 8- PREVALENCE OF DEPRESSIVE SYMPTOMATOLOGY AND ITS RELATIONSHIP TO HRQOL IN ARTHRITIS- A WEB-BASED HEALTH STATUS SURVEY

    May 1, 2003, 00:00

  • PCV35- COST EFFECTIVENESS ANALYSIS OF HMG-COA REDUCTASE INHIBITORS IN A MEDICAID POPULATION

    May 1, 2003, 00:00

  • PHP25- DOES THE PAST PREDICT THE FUTURE?

    May 1, 2003, 00:00

  • PHP45- DOES REDUCING LENGTH OF POSTOPERATIVE STAY REDUCE CANCELLATION OF OPERATIONS?

    May 1, 2003, 00:00

  • PGS3- LOW DOSE ESOMEPRAZOLE (20MG) USE IN GENERAL PRACTICE-A RETROSPECTIVE AUDIT

    May 1, 2003, 00:00

  • PAR 14- RETROSPECTIVE ANALYSIS OF THE IMPACT OF MEDICATION NONADHERENCE ON CLINICAL OUTCOMES AND COSTS IN PATIENTS WITH OSTEOPOROSIS RECEIVING ALENDRONATE USING AN INTEGRATED PAYOR DATABASE

    May 1, 2003, 00:00

  • PMH1- QUALITY ASSESSMENT OF META-ANALYSES OF RCTS OF PHARMACOTHERAPY IN MAJOR DEPRESSIVE DISORDER

    May 1, 2003, 00:00

  • PCV33- COST-EFFECTIVENESS ANALYSIS OF SIMVASTATIN AND LOVASTATIN/EXTENDED-RELEASE NIACIN TO ACHIEVE LDLAND HDL GOAL USING NHANES DATA

    May 1, 2003, 00:00

  • PRP9- THE NET COST OF ASTHMA TO NORTH CAROLINA (NC) MEDICAID AND IDENTIFICATION OF FACTORS DRIVING COSTS IN AN ASTHMATIC POPULATION

    May 1, 2003, 00:00

  • PDB25- COST ANALYSIS OF DIABETES TREATMENT WITH GLARGINE INSULIN OR NPH INSULIN IN SPAIN

    May 1, 2003, 00:00

  • PCV10- DEFINING OUTCOMES IN STUDIES OF BLEEDING MORBIDITY ASSOCIATED WITH ANTICOAGULATION THERAPY

    May 1, 2003, 00:00

  • PRK3- US MEDICAL VISITS WITH DIAGNOSES PATHOGNOMONIC OF OVERACTIVE BLADDER

    May 1, 2003, 00:00

  • PNP28- STUDY OF THE QUALITY OF LIFE IN PARKINSONS DISEASE PATIENTS IN RUSSIA

    May 1, 2003, 00:00

  • PMD31- COMPARING SHORT FORM 6D, STANDARD GAMBLE AND HEALTH UTILITIES INDEX MARK 2 AND MARK 3 UTILITY SCORES- RESULTS FROM TOTAL HIP ARTHROPLASTY PATIENTS

    May 1, 2003, 00:00

  • PNP3- USE OF WHOS ICIDH-2 CLASSIFICATION SYSTEM IN A FUNCTIONAL ASSESSMENT OF MIGRAINEURS

    May 1, 2003, 00:00

  • MD3- THE IMPACT OF REQUIRING A FIXED PERIOD OF ELIGIBILITY IN ECONOMIC AND EPIDEMIOLOGICAL STUDIES THAT UTILIZE LONGITUDINAL DATA

    May 1, 2003, 00:00

  • PRP11- CHANGES IN ASTHMA-RELATED HEALTHCARE UTILIZATION AND COSTS AFTER THE ADDITION OF SALMETEROL TO A MEDICAID POPULATION

    May 1, 2003, 00:00

  • PMH41- IMPACT OF DEPENDENTS DEPRESSION ON EMPLOYEE HEALTH BENEFITS COST- QUANTIFYING THE BURDEN OF CARE

    May 1, 2003, 00:00

  • PMH40- EVALUATING THE COST-EFFECTIVENESS OF ST. JOHNS WORT VERSUS FLUOXETINE FOR THE TREATMENT OF MILD TO MODERATE DEPRESSION

    May 1, 2003, 00:00

  • PRP15- RELATIONSHIP BETWEEN ADHERENCE RATE AND TOTAL MEDICAL AND DRUG COSTS

    May 1, 2003, 00:00

  • PHPIO- DOCUMENTING THE RESULTS OF CLINICAL INTERVENTIONS BY PHARMACISTS IN AN AMBULATORY SETTING

    May 1, 2003, 00:00

  • PWM2- A MULTIDIMENSIONAL ANALYSIS OF DELIVERY-CARE

    May 1, 2003, 00:00

  • PCV3- PREDICTORS OF ADHERENCE TO ANTIHYPERTENSIVES IN A MANAGED CARE POPULATION

    May 1, 2003, 00:00

  • PRK7- COMPARISON OF TACROLIMUS WITH CYCLOSPORIN IN KIDNEY TRANSPLANTATION- COST-MINIMISATION AND COSTEFFECTIVENESS ANALYSES

    May 1, 2003, 00:00

  • PGS8- UTILIZATION IMPACT OF PROTON PUMP INHIBITOR ON TREATMET COSTS FOR GASTROESOPHAGEAL REFLUX DISEASE USING HEALTH CARE CLAIMS DATA IN TAIWAN

    May 1, 2003, 00:00

  • PIN7- IMPACT OF THE GRIER CONSENT DECREE ON ANTIBIOTIC COSTS FOR TENNCARES MANAGED MEDICAID PROGRAM

    May 1, 2003, 00:00

  • AG2- RELATIONSHIP BETWEEN QUALITY OF LIFE AND COGNITIVE STATUS AMONG LONG-TERM CARE FACILITY RESIDENTS IN WEST VIRGINIA- A PILOT STUDY

    May 1, 2003, 00:00

  • PCN29- DEVELOPING A MEASUREMENT STRATEGY FOR PATIENT-REPORTED OUTCOMES- FINDINGS FROM THE NCIS CANCER OUTCOMES MEASUREMENT WORKING GROUP

    May 1, 2003, 00:00

  • PHP55- ASSOCIATION BETWEEN INCOME AND HEALTH STATUS IN THE ELDERLY CHINESE IN HONG KONG

    May 1, 2003, 00:00

  • PES19- DEVELOPMENT AND VALIDATION OF A HEALTH-RELATED QUALITY OF LIFE INSTRUMENT FOR WOMEN WITH MELASMA

    May 1, 2003, 00:00

  • PWM3- COMPARISON OF DIRECTTO-CONSUMER INTERVENTIONS BY A MEDICAID HEALTH PLAN TO INCREASE FOLIC ACID SUPPLEMENTATION IN WOMEN OF CHILDBEARING AGE

    May 1, 2003, 00:00

  • DP4- ARE SICK PEOPLE LESS RESPONSIVE TO PRESCRIPTION BENEFIT CHANGES?

    May 1, 2003, 00:00

  • PNP32- QUALITY OF LIFE (QOL) IN PATIENTS WITH PARTIAL EPILEPSY IN MOSCOW

    May 1, 2003, 00:00

  • PGS5- ECONOMIC ASSESSMENT OF DRUGS AND GI HOSPITALIZATIONS ASSOCIATED WITH APPLYING VA CRITERIA FOR PRESCRIBING NONSTEROIDAL ANTI-INFLAMMATORY AGENTS

    May 1, 2003, 00:00

  • PIN4- THE INFLUENCE OF PRESCRIPTION DRUG COVERAGE ON ANTIBIOTIC UTILIZATION IN ACUTE RESPIRATORY TRACT INFECTIONS- FINDINGS FROM THE MEDICAL EXPENDITURE PANEL SURVEY (MEPS)

    May 1, 2003, 00:00

  • PHP I 8- INCREASED HEALTHCARE UTILIZATION FOR THE ELDERLY DUE TO INAPPROPRIATE PRESCRIPTION USE

    May 1, 2003, 00:00

  • PDB15- COST-EFFECTIVENESS ANALYSIS OF GRAFTSKIN (APLIGRAF) AND BECAPLERMIN (REGRANEX) IN DIABETIC NEUROPATHIC FOOT ULCERS

    May 1, 2003, 00:00

  • PDB7- DIABETES RELATED DRUG UTILIZATION AND EXPENDITURES IN MEDICARE BENEFICIARIES WITH AND WITHOUT SUPPLEMENTAL PRESCRIPTION DRUG INSURANCE

    May 1, 2003, 00:00

  • PRP22- IS CISATRACURIUM COST EFFECTIVE FOR NEUROMUSCULAR BLOCKADE IN THE ICU? A MARKOV COMPUTER SIMULATION STUDY

    May 1, 2003, 00:00

  • PD4- LONGITUDINAL EXAMINATION OF OUTCOMES ASSOCIATED WITH BOTULINUM TOXIN USE IN CHILDREN WITH CEREBRAL PALSY

    May 1, 2003, 00:00

  • PD3- RELIABILITY AND VALIDITY OF KINDL CHILDREN GENERIC HEALTH-RELATED QUALITY OF LIFE QUESTIONNAIRE IN AN ASIAN SCHOOL-BASED SAMPLE

    May 1, 2003, 00:00

  • PDB2- IMPROVEMENT OF HEMOGLOBIN A1C (HBA1C) TESTING AND ANALYSIS OF PARTICIPANTREPORTED RESULTS IN CAREPATTERNS FOR DIABETES PROGRAM

    May 1, 2003, 00:00

  • PCV51- PREDICTIVE MODELS OF HEALTH-RELATED QUALITY OF LIFE UTILIZING PATIENT REPORTED OUTCOMES DATA FROM A POPULATION WITH A HISTORY OF ACUTE CORONARY SYNDROME

    May 1, 2003, 00:00

  • PARI 3- COMPLIANCE WITH DRUG THERAPIES FOR THE TREATMENT AND PREVENTION OF OSTEOPOROSIS

    May 1, 2003, 00:00

  • PGS7- COST-EFFECTIVENESS ANALYSIS OF ENDOSCOPIC SCLEROTHERAPY VERSUS LIGATION FOR THE PREVENTION OF REBLEEDING IN CHILDREN WITH OESOPHAGEAL VARICES

    May 1, 2003, 00:00

  • PMH9- INFLUENCE OF PHYSICIAN MIX AND SUPPLY ON THE DIFFUSION OF ATYPICAL ANTIPSYCHOTIC AGENTS

    May 1, 2003, 00:00

  • MH2- THE RELATIONSHIP OF ASTHMA AND GENERALIZED ANXIETY DISORDER IN ADULTS

    May 1, 2003, 00:00

  • PRP4- THE EFFECT OF A LETTER-BASED EDUCATIONAL PROGRAM FOR PRESCRIBERS AND PHARMACISTS ON ADHERENCE TO NATIONAL ASTHMA GUIDELINES AND HEALTHCARE UTILIZATION

    May 1, 2003, 00:00

  • EP4- ALLERGY PREVALENCE, COST AND PRODUCTIVITY LOSS IN AN INSURED EMPLOYEE POPULATION

    May 1, 2003, 00:00

  • PMDI7- ARE PUBLISHED COST-UTILITY ANALYSES IMPROVING?

    May 1, 2003, 00:00

  • ASI- CHANGES IN FUNCTIONAL DISABILITY LEVELS AND MEDICAL EXPENDITURES AMONG ELDERLY PERSONS

    May 1, 2003, 00:00

  • PMH14- CLINICAL PROFILES OF SSRI USERS- FACTS EXTRACTED FROM HEALTH CARE CLAIMS DATA

    May 1, 2003, 00:00

  • PMDI5- DO DIFFERENCES AMONG COST-EFFECTIVENESS ANALYSIS GUIDELINE RECOMMENDATIONS AFFECT POLICY CONCLUSIONS?

    May 1, 2003, 00:00

  • PHP24- GENERIC COMPETITION IN THE PHARMACEUTICAL INDUSTRY

    May 1, 2003, 00:00

  • PWM7- ECONOMIC BURDEN OF OSTEOPOROSIS, BREAST CANCER, AND CARDIOVASCULAR DISEASE AMONG WOMEN

    May 1, 2003, 00:00

  • PMD12- PHARMACOEPIDEMIOLGY-A REVIEW OF ITS EMERGING ROLE IN OUTCOMES RESEARCH

    May 1, 2003, 00:00

  • PCN9- PATIENT CHARACTERISTICS IMPACTING LENGTH OF STAY AND IN-PATIENT CHARGES AMONG US COLORECTAL CANCER PATIENTS

    May 1, 2003, 00:00

  • PMH16- PREVALENCE AND TRENDS IN ANTIPSYCHOTIC POLYPHARMACY AMONG MEDICAID ELIGIBLE SCHIZOPHRENIA PATIENTS IN CALIFORNIA AND GEORGIA, 1998-2000

    May 1, 2003, 00:00

  • PNP7- COMPLIANCE WITH THREE-TIMES DAILY METHYLPHENIDATE IN CHILDREN WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER

    May 1, 2003, 00:00

  • PDB114- RESOURCE UTILIZATION USING INNOLET VS. VIAL/SYRINGE FOR DAILY INSULIN INJECTION IN A SUBGROUP OF ELDERLY DIABETIC PATIENTS

    May 1, 2003, 00:00

  • PWM10- COST OF ACCESS BY FORMULARY TYPE- A CASE STUDY OF SILDENAFIL CITRATE IN A LARGE MANAGED CARE ORGANIZATION

    May 1, 2003, 00:00

  • PMH26- COST-EFFECTIVENESS OF ATYPICAL ANTIPSYCHOTICS IN ACUTE BIPOLAR MANIA

    May 1, 2003, 00:00

  • PGS4- EFFECT OF COMPETITION ON ANTIULCERGASTRIC-MEDICATION ACQUISITION COSTS FOR THE MEDICAID PROGRAM

    May 1, 2003, 00:00

  • DB4- MULTI-SITE EVALUATION OF DIABETES DISEASE MANAGEMENT PROGRAMS USING THE DIABETES MANAGEMENT EVALUATION TOOL (DMET)

    May 1, 2003, 00:00

  • PARI9- A UTILITY VALUATION STUDY ASSESSING TREATMENT OUTCOMES IN OSTEOARTHRITIS

    May 1, 2003, 00:00

  • PES12- AN APPRAISAL OF VISION-RELATED QUALITY OF LIFE INSTRUMENTS

    May 1, 2003, 00:00

  • PIN38- COST-EFFECTIVENESS OF LOPINAVIR/RITONAVIR COMPARED TO NELFINAVIR AS FIRST-LINE ANTIRETROVIRAL THERAPY IN TREATMENTNAVE HIV PATIENTS- A MANAGED CARE PERSPECTIVE

    May 1, 2003, 00:00

  • PIN18- INFLUENZA VACCINATION IN A MALAYSIAN COMPANY-WHAT RETURN ON INVESTMENT FOR THE EMPLOYER?

    May 1, 2003, 00:00

  • PDB26- EVALUATION OF QUALITY OF LIFE IN PATIENTS WITH NEUROPATHY USING THE NORFOLK QUALITY OF LIFE (QOL) TOOL

    May 1, 2003, 00:00

  • PMH44- UTILIZATION AND COST OF ATYPICAL ANTIPSYCHOTICS IN MEDICAID PATIENTS WITH DEPRESSION

    May 1, 2003, 00:00

  • DP3- PHYSICIAN ATTITUDE TOWARD ACADEMIC DETAILING AND OTHER DRUG COST-CONTAINMENT STRATEGIES IN A STATE HEALTH INSURANCE PROGRAM

    May 1, 2003, 00:00

  • PMH23 PHARMACOECONOMIC COMPARISON BETWEEN TWO DRUG STRATEGIES OF TREATMENT OF ANXIETY DISORDERS- HOMEOPATHY AND PSYCHOTROPICS

    May 1, 2003, 00:00

  • DPI- RELATIONSHIP BETWEEN DIRECT-TO-CONSUMER ADVERTISING AND PRODUCT INNOVATIVENESS

    May 1, 2003, 00:00

  • PCHI- SECOND TREATMENT PATTERNS IN PROSTATE CANCER PATIENTS WITH BIOCHEMICAL FAILURE- DATA FROM CAPSURE

    May 1, 2003, 00:00

  • PMD24- PROBABILISTIC SENSITIVITY ANALYSES- COMMONLY RECOMMENDED, UNCOMMONLY PERFORMED

    May 1, 2003, 00:00

  • MD2- COMPARISON OF PATIENT SELF-REPORTED HEALTHCARE RESOURCE UTILIZATION TO ELECTRONIC RECORD DATA- LESSONS LEARNED FROM A STUDY OF HERPES ZOSTER PATIENTS

    May 1, 2003, 00:00

  • PHP27- HEALTH RELATED QUALITY OF LIFE AMONG PRESCRIPTION DRUG USERS IN SWEDEN-AN EPIDEMIOLOGICAL SURVEY

    May 1, 2003, 00:00

  • PCHI5- AGREEMENT OF HEALTH UTILITIES INDEX SCORES AMONG SURVIVORS OF CANCER IN CHILDHOOD THEIR PARENTS AND THEIR DOCTORS IN URUGUAY

    May 1, 2003, 00:00

  • PIN49- HOW DOES PATIENT REPORT OF SYMPTOM IMPACT RELATE TO CLINICAL FUNCTIONING IN CHRONIC BRONCHITIS?

    May 1, 2003, 00:00

  • PMH54- MENTAL HEALTH COMORBIDITY PREVALENCE, PATTERNS, AND IMPACT ON QUALITY OF LIFE AMONG GULF WAR VETERANS

    May 1, 2003, 00:00

  • PCV5- CLINICAL EFFECTIVENESS OF AMLODIPINE ON SYSTOLIC BLOOD PRESSURE AS MONOTHERAPYAND IN COMBINATION

    May 1, 2003, 00:00

  • PCNI6- SPECIFIC CHOICES AND EXPENDITURES FOR HERBAL MEDICINES BY CANCER PATIENTS

    May 1, 2003, 00:00

  • PHP40- WORK IMPAIRMENT DUE TO CHRONIC DISEASE IN A POPULATION OF WISCONSIN SCHOOLTEACHERS

    May 1, 2003, 00:00

  • PCH4- ESTIMATING LIFE LOST DUE TO CANCER IN THE US-A COMPARISON OF LONGITUDINAL AND CROSS-SECTIONAL MEASURES

    May 1, 2003, 00:00

  • PAR3- IMPACT OF THE INTRODUCTION OF THE COX-2 INHIBITORS ON THE ANALGESIC MARKET IN A PUBLIC EMPLOYEES INDEMNITY INSURANCE PROGRAM- A FIVE YEAR STUDY

    May 1, 2003, 00:00

  • PAR9- THE IMPLICATIONS OF RHEUMATOID ARTHRITIS IN THE UK SECONDARY CARE HEALTH CARE SYSTEM

    May 1, 2003, 00:00

  • PHP 14- DEALIINGWITH PRESCRIPTION DRUGS- A NURSING HOME DILEMMA

    May 1, 2003, 00:00

  • PMH15- PREDICTORS OF DURATION OF VISITS AMONG PATIENTS DIAGNOSED WITH DEPRESSION IN THE AMBULATORY MEDICAL CARE SETTINGS

    May 1, 2003, 00:00

  • PCV8- ESTIMATING POPULATION BLOOD PRESSURE CONTROL AMONG US HYPERTENSIVE PATIENTS

    May 1, 2003, 00:00

  • EP3- WORK LOSS AND HEALTHCARE UTILIZATION AMONG U.S. EMPLOYEES WITH CHRONIC NON-CANCER PAIN

    May 1, 2003, 00:00

  • PHP9- FEASIBILITY OF HEALTH AND WELLNESS PROGRAMS VIA AN EMPLOYER-BASED INTRANET SITE

    May 1, 2003, 00:00

  • PMD28- ISPOR QUALITY OF LIFE SPECIAL INTEREST GROUP-TRANSLATION AND CULTURAL ADAPTATION- DEVELOPMENT OF PRINCIPLES OF BEST PRACTICE

    May 1, 2003, 00:00

  • CV4- EFFECTIVENESS OF AMLODIPINE VS. VALSARTAN UPON BLOOD PRESSURE CHANGE AND CONTROL AMONG HYPERTENSIVE ADULTS

    May 1, 2003, 00:00

  • PMD9- INTERNET-BASED PATIENT REGISTRIES IN COMMUNITY PRACTICE

    May 1, 2003, 00:00

  • PCHI4- MEDICAL TREATMENT FOR CHRONIC MYELOID LEUKAEMIA (CML)-AVERAGE COST EFFECTIVENESS RATIOS OF FIRST AND SECOND LINE TREATMENT

    May 1, 2003, 00:00

  • PES18- PSORIASIS AND QUALITY OF LIFE- SPANISH RESULTS

    May 1, 2003, 00:00

  • PHP47- PHYSICIAN HABITAS A DETERMINANT OF MEDICATION CHOICE

    May 1, 2003, 00:00

  • PIN15- ESTIMATING USAGE OF SELECTED ANTIINFECTIVE DRUGS IN U.S. HOSPITALS

    May 1, 2003, 00:00

  • DB3- ORAL ANTIHYPERGLYCEMIC MEDICATION NON-ADHERENCE AND SUBSEQUENT HOSPITALIZARON AMONG PERSONS WITH TYPE 2 DIABETES

    May 1, 2003, 00:00

  • PES14- IMPACT OF HYDROTHERAPY CARE ON THE QUALITY OF LIFE OF CHILDREN

    May 1, 2003, 00:00

  • PIN5- RELATIONSHIP BETWEEN PRESCRIPTION USE AND ANTIMICROBIAL RESISTANCE IN THE COMMUNITY-AN EXPLORATION

    May 1, 2003, 00:00

  • PMD33- RELATIONSHIP OF QUALITY OF LIFE DOMAINS TO PREFERENCE-BASED MEASURES OF QUALITY OF LIFE

    May 1, 2003, 00:00

  • PRP1- THE IMPLEMENTATION OF NEW TREATMENT GUIDELINES IN ASTHMA BY HEALTH CARE PROVIDERS

    May 1, 2003, 00:00

  • PMH5- THE IMPACT OF MIRTAZAPINE COMPARED TO NON-TCA ANTIDEPRESSANTS ON WEIGHT CHANGE IN NURSING FACILITY RESIDENTS

    May 1, 2003, 00:00

  • PRP10- PREDICTING THE BENEFIT OF OPTIMIZING SEVERE ASTHMA MANAGEMENT IN A MANAGED CARE SETTING-A COST-BENEFIT ANALYSIS COMPARING THE COMBINATION OF FLUTICASONE PROPIONATE AND SALMETEROL (FPS) AND ZAFIRLUKAST

    May 1, 2003, 00:00

  • PRP19- ASTHMA HEALTH CARE EXPENDITURE- THE ROLE OF CAPITATION AND MANAGED CARE

    May 1, 2003, 00:00

  • PNP30- CHANGES IN QUALITY OF LIFE RESULTING FROM TREATMENT FOR PERSONS WITH ADVANCED PARKINSONS DISEASE- SUMANIROLE VERSUS PLACEBO

    May 1, 2003, 00:00

  • PIN27- COST-EFFECTIVENESS OF CEFEPIME VERSUS CEFOTAXIME WHEN ADDED TO METRONIDAZOLE IN COMPLICATED INTRAABDOMINAL INFECTIONS

    May 1, 2003, 00:00

  • PGS11- INCIDENCE AND COST OF LAPAROSCOPIC CHOLECYSTECTOMY IN THE US MANAGED CARE POPULATION

    May 1, 2003, 00:00

  • ND4- ARE ELDERLY PATIENTS RECEIVING APPROPRIATE ANTIEPILEPTIC DRUGS?

    May 1, 2003, 00:00

  • PGS12- COST-MINIMIZATION ANALYSIS OF A PHARMACIST-DIRECTED, PANTOPRAZOLE INTRAVENOUS TO ORAL DOSAGE FORM CONVERSION PROGRAM

    May 1, 2003, 00:00

  • PHP2- THE ASSOCIATION OF PRACTICE GUIDELINES AND OTHER FACTORS WITH HOSPITAL LENGTH OF STAY (LOS) AND MORTALITY IN PATIENTS WITH COMMUNITY-ACQUIRED PNEUMONIA (CAP), HEART FAILURE (HF) AND SEDATED INTENSIVE CARE PATIENTS

    May 1, 2003, 00:00

  • PMH29- ECONOMIC BURDEN OF NOT RECOGNIZING BIPOLAR DISORDER PATIENTS

    May 1, 2003, 00:00

  • PRP25- CULTURAL ADAPTATION AND VALIDATION OF CHILDHOOD ASTHMA QUESTIONNAIRE-C (CAQ-C) IN SINGAPORE

    May 1, 2003, 00:00

  • PARI6- GASTROINTESTINAL (GI) SYMPTOMS AND HEALTH-RELATED QUALITY OF LIFE (HRQL) IN JUVENILE IDIOPATHIC ARTHRITIS (JIA)

    May 1, 2003, 00:00

  • PCV47- PREDICTING THE SAVINGS AND RETURN ON INVESTMENT OF TOBACCO CONTROL PROGRAMS IN A MANAGED CARE SETTING USING MEDISAVE SMOKING CESSATION

    May 1, 2003, 00:00

  • PMH6- EVALUATING THE EFFECTIVENESS OF FLUOXETINE 90MG ADMINISTERED EVERY WEEK AND EVERY 2 WEEKS IN NURSING HOME RESIDENTS

    May 1, 2003, 00:00

  • PMH45- COSTS AND EFFECTIVENESS OF METHADONE AND BUPRENORPHINE MAINTENANCE TREATMENTS IN WESTERN AUSTRALIA

    May 1, 2003, 00:00

  • MH4- DRUG UTILIZATION ANALYSIS OF THE SSRI CLASS IN A MEDICAID HMO-THE FLUOXETINE EXPERIENCE

    May 1, 2003, 00:00

  • PHP28- HEALTH INVOLVEMENT- RELATIONSHIP WITH HEALTH STATUS AND PATIENT SATISFACTION

    May 1, 2003, 00:00

  • PWM1- META-ANALYSIS OF THE EFFECTIVENESS OF MAMMOGRAPHY

    May 1, 2003, 00:00

  • PMH3- THE TREATMENT CHARACTERISTICS AND OUTCOMES OF PERSONS WITH DEPRESSION AND ALCOHOLISM

    May 1, 2003, 00:00

  • PNP11- MEDICAL CARE COSTS FOR TREATING ATTENTION DEFICIT/HYPERACTIVITY DISORDER-AN EMPIRICAL STUDY BASED ON A LARGE ADMINISTRATIVE CLAIM DATA

    May 1, 2003, 00:00

  • PMH58- COLLEGE STUDENTS AND STRESS-WHAT IS THE CONNECTION? A HUMANISTIC OUTCOMES ASSESSMENT

    May 1, 2003, 00:00

  • PCV52- WHICH STATIN? A MULTICRITERIA DECISION ANALYSIS

    May 1, 2003, 00:00

  • NDI- COST-EFFECTIVENESS OF TOPIRAMATE AS ADJUNCTIVE TREATMENT IN REFRACTORY EPILEPSY-A PROBABILISTIC ASSESSMENT OF TREATMENT STRATEGIES

    May 1, 2003, 00:00

  • PMD10- EVALUATING RETROSPECTIVE STUDY POSTERS PRESENTED AT THE ISPOR 7TH ANNUAL CONFERENCE

    May 1, 2003, 00:00

  • PCN24- DEVELOPMENT OF A PREFERENCE ELICITATION INSTRUMENT FOR USE IN PATIENTS WITH NEWLY DIAGNOSED BRAIN METASTASES IN A PROSPECTIVE RANDOMIZED CLINICAL TRIAL

    May 1, 2003, 00:00

  • PESI- FACTORS INFLUENCING A POTENTIALLY INAPPROPRIATE DERMATOLOGICAL MEDICATION COMBINATION PRESCRIPTION AMONG U.S. OUTPATIENT PHYSICIANS

    May 1, 2003, 00:00

  • PNP8- A MARKOV MODEL OF TREATMENT OF NEWLY DIAGNOSED EPILEPSY IN THE UK-AN ASSESSMENT OF COST-EFFECTIVENESS OF TOPIRAMATE

    May 1, 2003, 00:00

  • PCN6- DOSE CONVERSION OF ERYTHROPOIETIC AGENTS IN CHEMOTHERAPY-INDUCED ANEMIA-A META-ANALYSIS

    May 1, 2003, 00:00

  • PMH48- SUBJECTIVE TOLERABILITY WITH ZIPRASIDONE VS HALOPERIDOL IN ACUTE SCHIZOPHRENIA

    May 1, 2003, 00:00

  • PRK10- COST-MINIMISATION ANALYSIS AND ACCEPTANCE OF SELF-INJECTING SUBCUTANEOUSLY R-HUEPO WITH RECOPEN FOR MANAGEMENT OF ANAEMIA IN A POPULATION OF FRENCH ADULT PATIENTS ON DIALYSIS

    May 1, 2003, 00:00

  • PES17- IMPACT OF HYDROTHERAPY CARES ON THE QUALITY OF LIFE OF PATIENTS SUFFERING FROM SKIN DISEASES

    May 1, 2003, 00:00

  • PHP26- INAPPROPRIATE PRESCRIPTION DRUG USE AND REDUCED HEALTH STATUS FOR THE ELDERLY

    May 1, 2003, 00:00

  • QL2- CLINICAL IMPROVEMENT AND RESPONSIVENESS OF PHYSICAL FUNCTION MEASURES- TREATMENT WITH CTLA4IG (BMS-188667) IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS

    May 1, 2003, 00:00

  • PNP16- THE COMPARISON OF DIFFERENT METHODS FOR DETERMINING THE IMPACT OF MIGRAINE PROPHYLAXIS ON COSTS

    May 1, 2003, 00:00

  • DP2- ECONOMIC IMPACT OF PROZAC PATENT EXPIRATION AND THE 180-DAY GENERIC FLUOXETINE EXCLUSIVITY IN A PUBLICLY-FINANCED PRESCRIPTION PROGRAM

    May 1, 2003, 00:00

  • PRK4- COST ANALYSIS OF NON-DIALYSIS RENAL INSUFFICIENCY (NDRI)- AN EMPLOYERS PERSPECTIVE

    May 1, 2003, 00:00

  • CV2- CHOLESTEROL GOAL ATTAINMENT IN PATIENTS WITH DIABETES- EVIDENCE FROM MANAGED CARE

    May 1, 2003, 00:00

  • PHP54- EQUITY OF ACCESS TO HEALTH CARE SERVICES- AN EVIDENCE-BASED STUDY IN TAIWAN

    May 1, 2003, 00:00

  • PRK1- COMPARISON OF DIRECT HEALTH-CARE COST, HOSPITAL UTILIZATION AND MEDICATION PERSISTENCE BETWEEN EXTENDED RELEASE FORMS (ER) OF TOLTERODINE AND OXYBUTYNIN IN OVERACTIVE BLADDER/URINARY INCONTINENCE PATIENTS

    May 1, 2003, 00:00

  • PDI- SUICIDE ATTEMPTS BY ADOLESCENTS- HOSPITAL RESOURCE USE AND COSTS

    May 1, 2003, 00:00

  • PHP2I- PHARMACISTS UTILIZATION AND PERCEPTIONS OF DRUG INTERACTION PROGRAM WARNINGS

    May 1, 2003, 00:00

  • AD2- MEDICATION TREATMENT PERSISTENCE OF OVERACTIVE BLADDER/URINARY INCONTINENCE PATIENTS IN A CALIFORNIA MEDICAID PROGRAM AND THE BENEFIT OF THEIR REFILL ADHERENCE ON URINARY TRACK INFECTION

    May 1, 2003, 00:00

  • PIN14- POLICY EVALUATION FOR INFLUENZA VACCINATION OF ELDERLY IN JAPAN

    May 1, 2003, 00:00

  • PDB23- INVESTIGATOR AND SITE CHARACTERISTICS OF THE NAVIGATOR TRIAL

    May 1, 2003, 00:00

  • PIN19- ROUTINE CHILDHOOD VACCINATION AGAINST INFLUENZA-AN ANALYSIS OF CLINICAL AND ECONOMIC BENEFITS

    May 1, 2003, 00:00

  • AD 3- PREDICTIVE MODEL OF MEDICATION ADHERENCE IN CARDIOVASCULAR DISEASE

    May 1, 2003, 00:00

  • PRP20- IMPROVING PHARMACEUTICAL CARE BY THE PROCUREMENT OF PALIVIZUMAB THROUGH SPECIALTY DISTRIBUTION

    May 1, 2003, 00:00

  • PNP4- PHYSICIAN PERCEPTIONS ON THE USE OF MEDICATIONS FOR ATTENTION DEFICIT HYPERACTIVITY DISORDER

    May 1, 2003, 00:00

  • PDB28- DEVELOPMENT OF AN INSTRUMENT TO MEASURE PATIENT EXPECTATION AND PREFERENCE FOR THE INSULIN INJECTION PEN

    May 1, 2003, 00:00

  • MHI- GENDER VARIATION IN QUALITY OF PHARMACOLOGIC CARE OF CHILDREN DIAGNOSED WITH ATTENTIONDEFICIT/HYPERACTIVITY DISORDER (ADHD)

    May 1, 2003, 00:00

  • PRP16- RESOURCE UTILIZATION (HOSPITAL AND PHYSICIAN COST/VISITS) AFTER INTRODUCTION OF THE NEW TREATMENT GUIDELINES IN ASTHMA (1997)

    May 1, 2003, 00:00

  • PRK12- COMPARING SENSITIVITY TO CHANGE BETWEEN I-QOL AND SF-36 IN A POPULATION WITH URINARY INCONTINENCE

    May 1, 2003, 00:00

  • PIN33- MEDICAL RESOURCE USE AND DIRECT MEDICAL COST OF CHRONIC HEPATITIS B VIRUS (HBV) INFECTION IN BRAZIL

    May 1, 2003, 00:00

  • PDB6- FACTORS ASSOCIATED WITH HIGH-RISK DIABETIC PATIENTS IN THE CALIFORNIA MEDICAID POPULATIONS (MEDI-CAL)

    May 1, 2003, 00:00

  • PMH17- USE OF SEDATIVE/HYPNOTIC AGENTS BY AN ELDERLY AMBULATORY POPULATION

    May 1, 2003, 00:00

  • PAR7- ASSESSMENT OF THE BURDEN OF RHEUMATOID ARTHRITIS IN FRENCH HOSPITALS-ANALYSIS OF THE PMSI DATABASE

    May 1, 2003, 00:00

  • PCV7- TREATMENT OF PRIMARY PULMONARY HYPERTENSION (PPH)- A COST-UTILITY ANALYSIS

    May 1, 2003, 00:00

  • PRK9- COST-EFFECTIVENESS OF TAMSULOSIN, DOXAZOSIN AND TERAZOSIN IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA

    May 1, 2003, 00:00

  • PIN50- VALIDATION OF THE HEALTH RELATED PRODUCTIVITY QUESTIONNAIRE DIARY (HRPQ-D) ON A SAMPLE OF PATIENTS WITH INFECTIOUS MONONUCLEOSIS- RESULTS FROM AN OBSERVATIONAL STUDY

    May 1, 2003, 00:00

  • PCV14- RACIAL VARIATION IN THE UTILIZATION OF ANTIHYPERTENSIVE MEDICATIONS- AN ANALYSIS OF 1998 MEDICAL EXPENDITURE PANEL SURVEY (MEPS) DATA

    May 1, 2003, 00:00

  • PPT2- COST ANALYSIS OF PROPHYLACTIC TREATMENT OF CHILDREN WITH SEVERE HEMOPHILIA A IN CANADA

    May 1, 2003, 00:00

  • PMH49- PERFORMANCE OF THE SF-12 AND RAND-12 PHYSICAL AND MENTAL HEALTH SUMMARY SCORES IN PEOPLE PRACTICING MEDITATION

    May 1, 2003, 00:00

  • PPT7- IMPROVEMENT IN QUALITY OF LIFE AND HEALTHCARE UTILISATION DURING GROWTH HORMONE REPLACEMENT THERAPY IN HYPOPITUITARY ADULTS IN THE NETHERLANDS

    May 1, 2003, 00:00

  • PMH55- DO HEALTH EXPERIENCES IN DEPRESSION CHANGE PATIENTS VALUES?

    May 1, 2003, 00:00

  • PRP18- PHARMACOECONOMIC COMPARISON BETWEEN TWO DRUG STRATEGIES OF TREATMENT OF RECURRENT ACUTE RHINOPHARYNGITIS IN 18-MONTH-OLD TO 4-YEAR-OLD CHILDREN- HOMEOPATHY AND ANTIBIOTICS

    May 1, 2003, 00:00

  • PAR2- EFFECTS OF A PRIOR AUTHORIZATION POLICY FOR CYCLOOXYGENASE-2 INHIBITORS ON HEALTH-RELATED OUTCOMES IN A MANAGED CARE MEDICAID POPULATION

    May 1, 2003, 00:00

  • PMH53- IMPACT OF WEIGHT GAIN ON HEALTH-RELATED QUALITY OF LIFE (HRQL) OF BIPOLAR PATIENTS

    May 1, 2003, 00:00

  • PHP41- EVALUATION OF AN INTEGRATED WORKERS COMPENSATION/HEALTH INSURANCE PHARMACY BENEFIT PROGRAM- SATISFACTION, HEALTH OUTCOMES AND POTENTIAL COST SAVINGS

    May 1, 2003, 00:00

  • PWM9- ECONOMIC IMPACT OF SILDENAFIL CITRATE ON A PHARMACY BUDGET

    May 1, 2003, 00:00

  • PHP I 3- IMPROVING THE USE OF MEDICINES AND THE HEALTH KNOWLEDGE OF CONSUMERS THROUGH CIVIL EDUCATION SYSTEMS

    May 1, 2003, 00:00

  • PMH43- THE COST-UTILITY OF BUPROPION SR VERSUS SERTRALINE IN THE TREATMENT OF LATE-LIFE DEPRESSION

    May 1, 2003, 00:00

  • PIN25- A COST-EFFECTIVENESS ANALYSIS OF BACTERIAL ENDOCARDITIS PROPHYLAXIS FOR FEBRILE CHILDREN WITH CARDIAC LESIONS

    May 1, 2003, 00:00

  • ND3- ECONOMIC ANALYSIS OF ACUTE MIGRAINE THERAPY UTILIZATION WITHIN THE WISCONSIN STATE MEDICAID POPULATION

    May 1, 2003, 00:00

  • PRK11- THE ECONOMICS OF PHOSPHATE BINDERS IN RENAL DIALYSIS-A TWO-STAGE STRATEGY FOR MANAGING HYPERPHOSPHATEMIA

    May 1, 2003, 00:00

  • PIN39- IMPACT OF METABOLIC ABNORMALITIES (HYPERTENSION, DIABETES MELLITUS, HYPERLIPIDEMIA) ON RESOURCE CONSUMPTION AND HEALTH CARE COSTS IN HIV-INFECTED PATIENTS

    May 1, 2003, 00:00

  • PIN34- DIRECT MEDICAL COSTS ASSOCIATED WITH HEPATITIS B VIRUS (HBV) INFECTION IN THE UNITED STATES

    May 1, 2003, 00:00

  • PNP33- HOW DOES AN 11-POINT PAIN SCALE RELATE TO PREFERENCE ESTIMATES IN PATIENTS WITH CHRONIC PAIN AND CAN IT BE USED TO PREDICT PREFERENCES?

    May 1, 2003, 00:00

  • PIN29- PHARMACOECONOMIC EVALUATION OF ANTIMICROBIAL AGENTS IN THE TREATMENT OF SEXUALLY TRANSMITTED DISEASES IN LAGOS UNIVERSITY TEACHING HOSPITAL

    May 1, 2003, 00:00

  • PHP4I- PHARMACY REIMBURSEMENT FOR PHARMACEUTICAL CARE SERVICES IN AMBULATORY CARE SETTINGS AT US SCHOOLS OF PHARMACY

    May 1, 2003, 00:00

  • PMDI9- COMMUNITY OR PATIENT PREFERENCES FOR COST-UTILITY ANALYSES- DOES IT MATTER?

    May 1, 2003, 00:00

  • PDB1- RELATION BETWEEN MEDICATION COMPLIANCE AND GLUCOSE CONTROL IN PATIENTS WITH TYPE 2 DIABETES

    May 1, 2003, 00:00

  • PMD6- ESTIMATING THE TRAJECTORY-ADJUSTED IMPACT OF ACUTE EVENTS ON PATIENT-REPORTED OUTCOMES

    May 1, 2003, 00:00

  • PCV41- HOSPITAL COSTS AND CHARGES ATTRIBUTABLE TO THE DEVELOPMENT OF ARI/ARF AFTER CABG

    May 1, 2003, 00:00

  • PHP39- DOES POOR HEALTH STATUS LEAD TO LOWER INCOME PRODUCTIVITY?

    May 1, 2003, 00:00

  • PRK13- DEVELOPMENT OF A QUESTIONNAIRE TO ASSESS QUALITY OF CARE IN DUTCH DIALYSIS CENTERS

    May 1, 2003, 00:00

  • PCHI3- PHARMACOECONOMICAL ANALYSIS OF UNFRACTIONATED HEPARIN VERSUS DALTEPARIN IN PATIENTS WITH MALIGNANCIES

    May 1, 2003, 00:00

  • PCV36- COST-EFFECTIVENESS OF TREATING BY SIMVASTATIN 40 MG/DAY HIGH VASCULAR RISK PATIENTS- AN ECONOMIC EVALUATION BASED ON THE HEART PROTECTION STUDY

    May 1, 2003, 00:00

  • PES3- A MODEL-BASED PHARMACOECONOMIC ANALYSIS OF BRIMONIDINE TARTATE 0.2 AS AN ADJUNCTIVE THERAPY TO BETA-BLOCKERS IN THE TREATMENT OF GLAUCOMA OR OCULAR HYPERTENSION IN ADULT PATIENTS IN NORWAY

    May 1, 2003, 00:00

  • PIN44- THE COST OF SEVERE SEPSIS AT A TERTIARY CARE TEACHING INSTITUTION

    May 1, 2003, 00:00

  • PCV45- HOSPITALIZARON EXPENDITURE OF ACUTE RHEUMATIC FEVER AND CHRONIC RHEUMATIC HEART DISEASE IN THE UNITED STATES

    May 1, 2003, 00:00

  • PCV39- IMPACT OF ANEMIA ON HF HOSPITAL LENGTH OF STAY- LONGITUDINAL ANALYSIS OF A LARGE ADMINISTRATIVE DATABASE

    May 1, 2003, 00:00

  • PWM16- BENIGN PROSTATIC HYPERPLASIA- RECOGNITION OF THE CONSEQUENCES OF THE PATHOLOGY FOR THE SPOUSE

    May 1, 2003, 00:00

  • PHP49- HOSPITALIZATIONS RELATED TO DOMESTIC VIOLENCE- CHILD ABUSE BY A PARENT OR GUARDIAN

    May 1, 2003, 00:00

  • PNP15- COST-UTILITY ANALYSIS OF THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS WITH GLATIRAMER ACETATE OR INTERFERON BETA IN SPAIN

    May 1, 2003, 00:00

  • PMH39- DEPRESSION AND FIBROMYALGIA-TREATMENT AND COST WHEN DIAGNOSED SEPARATELY OR CONCURRENTLY

    May 1, 2003, 00:00

  • PCNI7- A WEIGHTED INDEX FORM OF THE FACT-L FOR USE IN ECONOMIC EVALUATION

    May 1, 2003, 00:00

  • PCHI8- ASSESSMENT OF PATIENT-REPORTED OUTCOMES AMONG PATIENTS WITH PROSTATE CANCER

    May 1, 2003, 00:00

  • PMD4- PERFORMANCE OF TWO CONDITIONAL EXPECTATION METHODS UNDER UNOBSERVED SELECTION BIAS

    May 1, 2003, 00:00

  • PMH35- ATYPICAL ANTIPSYCHOTICS-TREATMENT PATTERNS, UTILIZATION AND COST AMONG MANAGED CARE ENROLLEES

    May 1, 2003, 00:00

  • PMH2- A META-ANALYSIS AND COMMON COMPARATOR ANALYSIS OF OLANZAPINE VERSUS ZIPRASIDONE AND ARIPIPRAZOLE

    May 1, 2003, 00:00

  • PCV12- ACHIEVEMENT OF THE EUROPEAN ATHEROSCLEROSIS SOCIETY LDL-C TARGET BY HYPERCHOLESTEROLAEMIC PATIENTS RECEIVING ROSUVASTATIN COMPARED TO ATORVASTATIN, PRAVASTATIN OR SIMVASTATIN- AN EVIDENCE-BASED MEDICINE APPROACH

    May 1, 2003, 00:00

  • PWM15- BPH- CONSEQUENCES ON THE SPOUSES SEXUALITY

    May 1, 2003, 00:00

  • QLI- QUALITY OF LIFE, UTILITY, AND WILLINGNESS TO PAY IN PATIENTS WITH DIABETES

    May 1, 2003, 00:00

  • PMD11- BEST PRACTICES- EVALUATING MODELING RESEARCH AT ISPOR USING BMJAND ISPOR GUIDELINES

    May 1, 2003, 00:00

  • PHP46- CHARACTERISTICS AND RISK FACTORS FOR HOSPITAL READMISSION IN MEDICAID POPULATION

    May 1, 2003, 00:00

  • PRP3- CLINICAL EFFECTIVENESS OF BUDESONIDE AND FORMOTEROL IN A SINGLE INHALER IN PATIENTS WITH ASTHMA-AN AUDIT IN UK GENERAL PRACTICE

    May 1, 2003, 00:00

  • PCV38- A COST AND COST-EFFECTIVENESS (CE) ANALYSIS OF ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITORTRANDOLAPRIL IN THE TREATMENT OF POST INFARCTION IN THE US

    May 1, 2003, 00:00

  • PRK5- ANALYSIS OF COMORBIDITY, HOSPITAL UTILIZATION AND COST OF OVERACTIVE BLADDER IN A CALIFORNIA MEDICAID PROGRAM-A CASE-CONTROL STUDY

    May 1, 2003, 00:00

  • PMH21- REINFORCE AND ADVOCATE COMMUNITY AND SCHOOL EDUCATIONAL PROGRAM IN SAFETY USE OF MEDICATION AND PREVENTION OF DRUG ABUSE IN CENTRAL OF TAIWAN

    May 1, 2003, 00:00

  • PIN46- HIV/AIDS PATIENTS- EXPERIENCES WITH HOSPITALIZATION

    May 1, 2003, 00:00

  • PCN21- DIFFERENCES IN HUSBAND/WIFE PREFERENCES AND UTILITIES FOR PROSTATE CANCER THERAPIES

    May 1, 2003, 00:00

  • PARI- USE OF ALTERNATIVE THERAPY, QUALITY OF LIFE AND HEALTHCARE SPENDING IN CHINESE PATIENTS WITH OSTEOARTHRITIS

    May 1, 2003, 00:00

  • PPT1- COST-EFFECTIVENESS OF RECOMBINANT HUMAN ERYTHROPOIETIN FOR PREVENTING TRANSFUSIONS IN CRITICALLY ILL PATIENTS

    May 1, 2003, 00:00

  • PNP20- COST UTILITY ANALYSIS OF IMMUNOGLOBULINS (IVIG) VERSUS PLASMA EXCHANGE (PE) FOR THE TREATMENT OF GUILLAIN BARRE SYNDROME (GBS)

    May 1, 2003, 00:00

  • PWM5- FEASIBILITY OF SIMPLIFYING COMPLEX DECISION TREES VIA LINEAR REGRESSION ANALYSIS-AN APPLICATION TO COST-EFFECTIVENESS ANALYSIS OF HORMONE THERAPY FOR MENOPAUSAL SYMPTOMS

    May 1, 2003, 00:00

  • PDB22- THE DIRECT COST OF DIABETES TYPE 2 IN POLAND-PRELIMINARY DATA FROM CODIP STUDY

    May 1, 2003, 00:00

  • PRK15- DISEASE-SPECIFIC PATIENT-REPORTED OUTCOME MEASURES IN URINARY INCONTINENCE

    May 1, 2003, 00:00

  • PGS6- THE COST-EFFECTIVENESS OF ALTERNATIVE STRATEGIES IN THE MANAGEMENT OF PATIENTS WITH UNINVESTIGATED DYSPEPSIA (UD)- COMPARING THE CANDYS APPROACH TO EMPIRICAL ANTISECRETORY THERAPY AND PROMPT ENDOSCOPY

    May 1, 2003, 00:00

  • AC4- INAPPROPRIATE DRUG PRESCRIBING IN OUTPATIENT CARE FOR THE ELDERLY-THE CASE OF POTENTIALLY HARMFUL DRUG-DRUG AND DRUG-DISEASE COMBINATIONS

    May 1, 2003, 00:00

  • PMD37- IMPACT OF SOCIODEMOGRAPHICS ON QUALITY OF LIFE DOMAINS

    May 1, 2003, 00:00

  • PIN36- COST-SAVINGS OF AN IV TO PO ACYCLOVIR SWITCH IN A STANDARDIZED HSV PROPHYLAXIS PROTOCOL ON A BMT UNIT

    May 1, 2003, 00:00

  • PCH3- PERFORMANCE OF THE MC-PEEK-SCORE FOR SURGICAL OUTCOME

    May 1, 2003, 00:00

  • PMH47- VALIDATION OF ENGLISH AND CHINESE VERSIONS OF THE SQLS, SF-36 AND HUI3 IN PATIENTS WITH SCHIZOPHRENIA IN SINGAPORE

    May 1, 2003, 00:00

  • PCV19- SMOKING CESSATION- RELEVANCE IN THE UNDER 25 GROUP

    May 1, 2003, 00:00

  • PGS1- IMPACT OF RISK MODELING INFORMATION ON THE PRESCRIBING OF COX-2 INHIBITOR AGENTS

    May 1, 2003, 00:00

  • PIN1- ASSOCIATION BETWEEN SKIN TATTOOS AND HEPATITIS B OF 1/2000 PRIVATES AT ADISORN FORT HOSPITAL, THAILAND

    May 1, 2003, 00:00

  • PMH27- EFFECTS OF PATIENTS WITH BIPOLAR, SCHIZOPHRENIC, AND MAJOR DEPRESSIVE DISORDERS ON THE MENTAL AND OTHER HEALTHCARE EXPENSES OF FAMILY MEMBERS

    May 1, 2003, 00:00

  • PAR8- COST BURDEN OF HIP AND KNEE REPLACEMENTS IN OHIO AND IN THE UNITED STATES- ESTIMATED FROM THE NATIONAL HOSPITAL DISCHARGE SURVEY 2000

    May 1, 2003, 00:00

  • PNP23- COST-EFFECTIVENESS OF DRUG THERAPY FOR POSTHERPETIC NEURALGIA

    May 1, 2003, 00:00

  • PDB13- USING LINEAR REGRESSION TO APPROXIMATE RESULTS OF DECISION ANALYSIS- AN APPLICATION TO A COST COMPARISON ACROSS THREE FIRST-LINE DRUG STRATEGIES IN TYPE 2 DIABETES

    May 1, 2003, 00:00

  • PES9- A BASELINE ASSESSMENT OF THE VALIDITY OF THE 39-ITEM NATIONAL EYE INSTITUTE VISUAL FUNCTION QUESTIONNAIRE IN GERMAN PATIENTS WITH AGE-RELATED MACULAR DEGENERATION

    May 1, 2003, 00:00

  • PMD5- IMPROVING REPORTS OF PRO DATA TO SUPPORT AN EFFECTIVENESS CLAIM

    May 1, 2003, 00:00

  • PIN11- DYSLIPIDEMIA MANAGEMENT AMONG HIVINFECTED PATIENTS TREATED WITH PROTEASE INHIBITORS (PI)

    May 1, 2003, 00:00

  • PIN31- THE COST-EFFECTIVENESS OF PEGINTERFERON ALFA-2A (40KD) (PEGASYS) PLUS RIBAVIRIN (COPEGUS) VS. INTERFERON ALFA-2B PLUS RIBAVIRIN FOR CHRONIC HEPATITIS C (CHC)

    May 1, 2003, 00:00

  • PIN24- COST EFFECTIVENESS ANALYSIS OF LINEZOLID VS. TEICOPLANIN FOR THE TREATMENT OF SERIOUS GRAM-POSITIVE BACTERIAL INFECTIONS IN A MULTINATIONAL RANDOMIZED TRIAL

    May 1, 2003, 00:00

  • PIN26- LIFETIME GOVERNMENTAL COSTS OF SEVERE SEQUELAE OF PNEUMOCOCCAL MENINGITIS IN A WELFARE STATE

    May 1, 2003, 00:00

  • PGS13- DIFFERENCES BETWEN ELDERLY AND YOUNGER ADULTS IN THE EPIDEMIOLOGY AND TREATMENT OF SYMPTOMATIC GERD AND NOCTURNAL GERD

    May 1, 2003, 00:00

  • PRP7- USE OF LONG-TERM ASTHMA CONTROLLER MEDICATIONS BEFORE AND AFTER A HOSPITALIZATION OR EMERGENCY DEPARTMENT VISIT

    May 1, 2003, 00:00

  • PNP14- COST OF MULTIPLE SCLEROSIS BY LEVEL OF DISABILITY

    May 1, 2003, 00:00

  • PMD23- IS MARKOV CHAIN/DECISION TREE APPROACH BETTER THAN COST FUNCTION APPROACH IN MODELING THE PHARMACEUTICAL COSTS FOR ATTENTION DEFICIT/HYPERACTIVITY DISORDER? AN EMPIRICAL STUDY BASED ON A LARGE CLAIM DATABASE

    May 1, 2003, 00:00

  • PHP5- CORRELATIONS BETWEEN A STAGE OF CHANGE MEASURE AND FOUR VALIDATED MEASURES OF MEDICATION COMPLIANCE

    May 1, 2003, 00:00

  • PDB18- ESTIMATING THE COST-EFFECTIVENESS OF REPAGLINIDE PLUS METFORMIN VS. NATEGLINIDE PLUS METFORMIN OVER A 30-YEAR PERIOD

    May 1, 2003, 00:00

  • PHP 19- PRESCRIPTION DRUG UTILIZATION PATTERNS AND CHARACTERISTICS OF RETAIL AND MAIL ORDER PHARMACY UTILIZERS

    May 1, 2003, 00:00

  • PIN22- TELITHROMYCIN (TEL) IS AN EFFECTIVE THERAPY FOR ADULT OUTPATIENTS WITH COMMUNITY-ACQUIRED PNEUMONIA (CAP) AND IS ASSOCIATED WITH LOWER OVERALL HEALTHCARE COSTS THAN CLARITHROMYCIN (CLA)-A POOLED ANALYSIS OF DATA FROM TWO INDEPENDENT, ...

    May 1, 2003, 00:00

  • PCV6- A REVIEW OF THE PHARMACOTHERAPEUTIC MANAGEMENT OF PULMONARY ARTERIAL HYPERTENSION

    May 1, 2003, 00:00

  • PRK2- FACTORS ASSOCIATED WITH DIALYSIS TREATMENT COSTS AMONG MEDICARE ENROLEES

    May 1, 2003, 00:00

  • PWM6- A COMPARISON OF RESOURCE UTILIZATION FROM INPATIENT VERSUS OUTPATIENT SURGERY-THE CASE OF LAPAROSCOPIC HYSTERECTOMY IN FLORIDA

    May 1, 2003, 00:00

  • PHP35- AN ANALYSIS OF THE HEALTH AND PRODUCTIVITY COST BURDEN OF THE PHYSICAL AND MENTAL HEALTH CONDITIONS AFFECTING SIX LARGE CORPORATIONS IN 1999

    May 1, 2003, 00:00

  • PES11- QUALITY OF LIFE IN PATIENTS WITH AGERELATED MACULAR DEGENERATION-A CONJOINT ANALYSIS APPROACH

    May 1, 2003, 00:00

  • PMH36- ECONOMIC EVALUATION OF ATYPICAL ANTIPSYCHOTICS WITHIN THE WISCONSIN MEDICAID PROGRAM

    May 1, 2003, 00:00

  • PES4- COST-EFFECTIVENESS OF BIMATOPROST 0.03 FOR GLAUCOMA

    May 1, 2003, 00:00

  • PHP I 5- PUBLIC SUBSIDY OF PHARMACEUTICALS- THE ECONOMIC CASE FOR AND AGAINST GOVERNMENT INTERVENTION

    May 1, 2003, 00:00

  • PHP4- BIAS IN CATEGORICAL MEDICATION COMPLIANCE ASSESSMENT

    May 1, 2003, 00:00

  • PCV44- EVALUATION ON THE COST OF MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION IN A LOCAL PUBLIC HOSPITAL IN HONG KONG

    May 1, 2003, 00:00

  • PIN32- COST-EFFECTIVENESS ANALYSIS OF ANTIVIRAL THERAPIES FOR CHRONIC HEPATITIS B IN TAIWAN

    May 1, 2003, 00:00

  • CV6- NONCONFORMANCEWITH NCEP-ATP III RECOMMENDATION ON LIPID/LIPOPROTEIN MEASUREMENT AT BASELINE- A RISK FACTOR FOR EMERGENCY OR HOSPITALIZATION?

    May 1, 2003, 00:00

  • PMH42- TREATMENT OF DEPRESSION- ESCITALOPRAM HAS SIMILAR EFFICACY BUT LOWER COSTS COMPARED TO VENLAFAXINE XR

    May 1, 2003, 00:00

  • PIN28- ESTIMATED COST SAVINGS OF DISCONTINUING SECONDARY PROPHYLAXIS FOR OPPORTUNISTIC INFECTIONS AFTER IMMUNOLOGICAL RECONSTITUTION WITH HAART

    May 1, 2003, 00:00

  • PMD14- DEVELOPING A HEALTH ECONOMIC EVALUATION DATABASE IN JAPAN- JEED PROJECT

    May 1, 2003, 00:00

  • PCV13- ENOXAPARIN USE IN PATIENTS WITH MECHANICAL HEART VALVES REQUIRING BRIDGING THERAPY FOR SUBTHERAPEUTIC CHRONIC ORAL ANTICOAGULATION

    May 1, 2003, 00:00

  • PCV50- DESCRIPTION AND PREDICTIVE MODELING OF PERCEIVED WORK PERFORMANCE IN AN ACUTE CORONARY SYNDROME POPULATION

    May 1, 2003, 00:00

  • PES10- PATIENT REPORTED OUTCOMES AND ECONOMIC IMPLICATIONS OF A REFORMULATION TO IMPROVE BRIMONIDINE 0.2

    May 1, 2003, 00:00

  • PRP23- ECONOMIC OUTCOMES OF TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH INHALED CORTICOSTEROIDS AND LONG-ACTING b-AGONISTS IN A HEALTH MAINTENANCE ORGANIZATION

    May 1, 2003, 00:00

  • PIN2- TELITHROMYCIN (TEL) RESULTS IN FEWER HOSPITALIZATIONS THAN AMOXICILLINCLAVULANATE (AMC) IN THE OUTPATIENT TREATMENT OF ACUTE EXACERBATIONS OF CHRONIC BRONCHITIS (AECB)

    May 1, 2003, 00:00

  • PCHI2- ECONOMIC BURDEN OF ACTINIC KERATOSIS AND SQUAMOUS CELL CARCINOMA IN AMBULATORY CARE

    May 1, 2003, 00:00

  • PMH56- QUALITY OF LIFE TRAJECTORIES AMONG MASSACHUSETTS ADULTS WITH SUBSTANCE USE DISORDERS

    May 1, 2003, 00:00

  • PCNI9- QUALITY OF LIFE PROFILE OF MEN AT-RISK FOR PROSTATE CANCER-THE FIT AND THE WORRIED WELL

    May 1, 2003, 00:00

  • PHP37- UTILIZATION PATTERNS AND RISK FACTORS FOR HIGH COST RECIPIENTS IN MEDICAID POPULATION

    May 1, 2003, 00:00

  • PHP36- COSTS ASSOCIATED WITH FALLS IN COMMUNITY DWELLING ELDERS

    May 1, 2003, 00:00

  • AD I- NON-PROCUREMENT OF PRESCRIPTION MEDICATIONS DUE TO COST IN MEDICARE BENEFICIARIES- RESULTS FROM THE HEALTH AND RETIREMENT STUDY

    May 1, 2003, 00:00

  • PDB24- FACTORS INFLUENCING THE DIAGNOSTIC TESTS PRESCRIBING FOR TYPE 2 DIABETES IN AMBULATORY PATIENTS

    May 1, 2003, 00:00

  • PHP44- ROLES OF DIFFERENT TYPES OF HEALTH INSURANCE ON ACCESS AND UTILIZATIONS COMPARISON BETWEEN DIABETIC AND HYPERTENSIVE PATIENTS IN THE USA

    May 1, 2003, 00:00

  • PCV31- ECONOMIC IMPACT OF UNCONTROLLED HYPERTENSION AMONG NSAID USERS

    May 1, 2003, 00:00

  • PES13- COMPARING THE QUALITY OF LIFE EFFECTS OF PRIMARY FOCAL HYPERHIDROSIS TO OTHER DERMATOLOGICAL CONDITIONS AS ASSESSED BY THE DERMATOLOGY LIFE QUALITY INDEX (DLQI)

    May 1, 2003, 00:00

  • PPT6- HEMOPHILIA ECONOMIC MODEL OF OUTCOMES- CASE STUDY

    May 1, 2003, 00:00

  • PNP34- PATIENT PREFERENCE-BASED TREATMENT RECOMMENDATIONS FOR ENDOMETRIOSIS PAIN- CHOICE OF METHOD MATTERS

    May 1, 2003, 00:00

  • PDB4- OBTAINING QUALITY REAL-WORLD TREATMENT DATA FOR ECONOMIC MODELS- METHODOLOGY AND RESULTS OF A WOUND CARE MEDICAL RECORD ABSTRACTION STUDY

    May 1, 2003, 00:00

  • PCV18- A CONFIRMATORY FACTOR ANALYSIS EVALUATION OF THE CORONARY HEART DISEASE RISK FACTORS OF METABOLIC SYNDROME AND THE EFFECTIVENESS OF THE CURRENT ATP III GUIDELINES FOR IDENTIFICATION

    May 1, 2003, 00:00

  • PRP21- THE ECONOMIC IMPACT OF HOMEOPATHIC MANAGEMENT- THE FRENCH EXAMPLE

    May 1, 2003, 00:00

  • PWM13- PREDICTORS OF RESPONSE TO ERECTILE DYSFUNCTION TREATMENT AT 12 MONTHS- RESULTS FROM THE EXCEED DATABASE

    May 1, 2003, 00:00

  • PHP8- DIFFERENTIAL ECONOMIC IMPACT OF VARIABLE COMPLIANCE AND VARIABLE PERSISTENCE WITH PRESCRIBED, LONG-TERM DRUG REGIMENS

    May 1, 2003, 00:00

  • PNP24- ESTIMATES AND PATTERNS OF HEALTHCARE EXPENDITURES AMONG INDIVIDUALS WITH BACK PAIN IN THE US

    May 1, 2003, 00:00

  • PCV4- THE EFFECT OF STATIN DOSE ON ATTAINMENT OF TARGET LDL-C LEVELS

    May 1, 2003, 00:00

  • PCV25- AN INVESTIGATION OF THE CARE NEEDS AFTER ACUTE ISCHEMIC STROKE- AN ANALYSIS OF THE DATA COLLECTED IN THE ERLANGEN STROKE PROJECT

    May 1, 2003, 00:00

  • PNP31- PARENT PERCEPTIONS OF MEDICATIONS FOR ADHD-A PILOT STUDY

    May 1, 2003, 00:00

  • MH3- EVALUATING THE ECONOMIC CONSEQUENCES OF EARLY SSRI DROP-OUTS IN DEPRESSION

    May 1, 2003, 00:00

  • PHP34- IMPROVING OUTCOMES THROUGH ACCESS TO CRITIQUED ECONOMIC EVALUATIONS-THE NHS ECONOMIC EVALUATION DATABASE WITHIN THE HTA REVIEW PROCESS

    May 1, 2003, 00:00

  • PMH51- IMPACT OF COMORBID DIABETES ON FUNCTIONING IN SCHIZOPHRENIA

    May 1, 2003, 00:00

  • Disclosure Information

    May 1, 2003, 00:00

  • PHP50- DOMESTIC VIOLENCE- HOSPITALIZATIONS RESULTING FROM ABUSE BY A SPOUSE OR PARTNER

    May 1, 2003, 00:00

  • PHP IO- IMPACT OF RISK DISCLOSURES IN DIRECT-TO-CONSUMER ADVERTISING ON ELDERLY CONSUMERS BEHAVIORAL INTENT

    May 1, 2003, 00:00

  • PIN10- THE ALLOCATION OF HIV PREVENTION FUNDS

    May 1, 2003, 00:00

  • PCV48- COMPARISON OF WEIGHT-RELATED QUALITY OF LIFE IMPACTS BY AGE AND GENDER

    May 1, 2003, 00:00

  • PCH8- PREVALENCE RATES AND COST OF DEPRESSION AMONG PROSTATE CANCER PATIENTS

    May 1, 2003, 00:00

  • Abstracts Index

    May 1, 2003, 00:00

  • AD4- A TIME-VARYING SURVIVAL MODEL FOR THE ASSOCIATION OF ADHERENCE WITH HMG-COA INHIBITORS TO THE RISK OF ADVERSE EVENTS

    May 1, 2003, 00:00

  • PNP19- COST PER SUCCESSFULLY TREATED PATIENT AS MEASURE OF EFFECTIVENESS IN COMPARING ELETRIPTAN TO SUMATRIPTAN

    May 1, 2003, 00:00

  • PRP6- COMPARISON OF RISK FOR HOSPITAL AND/OR EMERGENCY DEPARTMENT VISITS FOR MEDICAID PATIENTS WITH COPD

    May 1, 2003, 00:00

  • PIN45- THE COST EFFECTIVENESS OF PI BASED THERAPY WITH NELFINIVIR (NLF) COMPARED TO RITONAVIR (RTV) FOR PATIENTS WITH HIV/AIDS

    May 1, 2003, 00:00

  • PDB9- IMPACT OF AGE, GENDER, AND OUT-OFPOCKET COSTS ON THE TIME TO DISCONTINUATION OF ORAL ANTI-DIABETIC AGENTS AMONG PATIENTS WITH TYPE 2 DIABETES

    May 1, 2003, 00:00

  • PCV28- ECONOMIC OUTCOMES ASSOCIATED WITH CHOICE OF TREATMENT IN DEEP VENOUS THROMBOSIS AND PULMONARY EMBOLISM

    May 1, 2003, 00:00

  • PPT9- HEALTHCARE CONSUMPTION, QOL, AND PATIENT-REPORTED OUTCOMES DURING GH REPLACEMENT IN HYPOPITUITARY ADULTS- RESULTS FROM THE GERMAN KIMS COHORT

    May 1, 2003, 00:00

  • PCV29- HEALTH SERVICE UTILIZATION, COSTS AND OUTCOMES OF PATIENTS WHO USED DIFFERENT TYPES OF CALCIUM CHANNEL BLOCKERS FOR HYPERTENSION

    May 1, 2003, 00:00

  • PNP17- THE ECONOMIC BURDEN OF MIGRAINE AND COMORBID MENTAL CONDITIONS- RESULTS FROM A CASE-CONTROL STUDY

    May 1, 2003, 00:00

  • PIN9- IMPACT OF CHANGES IN REIMBURSEMENT POLICY ON ANTIBIOTIC USE AND EXPENDITURES

    May 1, 2003, 00:00

  • PMH50- COMORBID DIABETES AND SCHIZOPHRENIA- IMPACT ON HEALTHCARE RESOURCE USE

    May 1, 2003, 00:00

  • PWM4- EVALUATION OF A PHARMACEUTICAL PATIENT ASSISTANCE PROGRAM-THE NORPLANT REMOVAL PROGRAM

    May 1, 2003, 00:00

  • PES6- ECONOMIC EVALUATION OF PHOTODYNAMIC THERAPY WITH VERTEPORFIN FOR SMALL SUBFOVEAL CNV LESIONS-THE CASE OF AUSTRALIA

    May 1, 2003, 00:00

  • PMD27- DO PHARMACOECONOMIC FELLOWSHIP PROGRAMS PROVIDE THE SKILLS NECESSARY FOR TODAYS WORK ENVIRONMENT?

    May 1, 2003, 00:00

  • DBI- IMPACT OF PARTICIPANT COST-SHARE ON COMPLIANCE RATES IN PARTICIPANTS WITH DIABETES

    May 1, 2003, 00:00

  • PMDI- A NEW METHOD FOR TIME ADJUSTMENT OF THE NUMBER NEEDED TO TREAT REGARDING VARIABLE RELATIVE RISK REDUCTION

    May 1, 2003, 00:00

  • PMH12- ASSESSING THE RELATIONSHIP OF GENERALIZED ANXIETY DISORDER AND PEPTIC ULCER DISEASE

    May 1, 2003, 00:00

  • EP2- COST ANALYSIS OF HEPATITIS C VIRUS (HCV) INFECTION-AN EMPLOYERS PERSPECTIVE

    May 1, 2003, 00:00

  • PMH31- PATTERNS OF TREATMENT AMONG BIPOLAR DISORDER PATIENTS TREATED WITH ANTIDEPRESSANTS

    May 1, 2003, 00:00

  • PHP52- VARIATIONS IN UTILIZATION RATES, CLINICAL TRIGGERS AND OUTCOMES OF X-RAYS IN A DEVELOPING COUNTRY

    May 1, 2003, 00:00

  • PIN21- COST-EFFECTIVENESS OF SELECTED INTERVENTIONS TO REDUCE THE BURDEN OF CHILDHOOD PNEUMONIA AND DIARRHEA- A STANDARDISED ANALYSIS

    May 1, 2003, 00:00

  • PMH37- THE ECONOMIC BURDEN OF DEPRESSION IN 2000

    May 1, 2003, 00:00

  • PIN12- IMPLICATIONS OF APPLYING DIFFERENT NATIONAL GUIDELINES ADDRESSING SURGICAL ANTIBIOTIC PROPHYLAXIS- A CROSS SECTIONAL STUDY OF 386 PATIENTS UNDERGOING TOTAL HIP REPLACEMENT SURGERY

    May 1, 2003, 00:00

  • PCV11- EFFECTIVENESS OF CLINICAL PATHWAYS FOR PATIENTS WITH HEART FAILURE

    May 1, 2003, 00:00

  • PCN2 3- HEALTH-RELATED QUALITY OF LIFE BURDEN OF HEAD AND NECK CANCER

    May 1, 2003, 00:00

  • PIN43- THE EFFECT OF HEALTH PERCEPTION IN MODIFYING TOTAL HEALTH CARE EXPENDITURES WITHIN AN IMMUNIZED ELDERLY UNITED STATES POPULATION

    May 1, 2003, 00:00

  • PRP8- COMPARISON OF THE ECONOMIC IMPACT OF MONTELUKAST AND INHALED CORTICOSTEROID AGENTS ON ALLERGIC RHINITIS-RELATED UTILIZATION IN PATIENTS WITH ASTHMA

    May 1, 2003, 00:00

  • PARI2- COST-EFFECTIVENESS OF RALOXIFENE FOR THE PREVENTION OF OSTEOPOROTIC FRACTURES IN AUSTRALIA

    May 1, 2003, 00:00

  • PHP7- CRITICAL EVALUATION OF INTERVENTIONS TO ENHANCE PATIENT COMPLIANCE WITH CHRONIC MEDICATIONS

    May 1, 2003, 00:00

  • PMH4- ANALYSIS OF HEALTHCARE UTILIZATION PATTERNS AND ADHERENCE IN PATIENTS RECEIVING ANTIPSYCHOTIC MEDICATIONS

    May 1, 2003, 00:00

  • PMH8- PHARMACOLOGIC TREATMENT OF HOSPITALIZED PATIENTS WITH BIPOLAR DISORDER

    May 1, 2003, 00:00

  • PMD25- INCREASING PUBMEDYIELD FOR PHARMACOECONOMIC RESEARCH USING ITERATIVE SEARCH STRATEGIES

    May 1, 2003, 00:00

  • CV8- CURRENT PATTERNS OF CARE AND TREATMENT COSTS ASSOCIATED WITH VENOUS THROMBOEMBOLIC DISEASE

    May 1, 2003, 00:00

  • PIN42- COST OF VARICELLA IN POLAND

    May 1, 2003, 00:00

  • PMH57- PSORIASIS, QUALITY OF LIFE AND DEPRESSIVE SYMPTOMATOLOGY-FRENCH RESULTS

    May 1, 2003, 00:00

  • PCV21- TREATMENT PATTERNS AMONG NEWLY DIAGNOSED CORONARY HEART DISEASE PATIENTS- CORRELATES OF LIPID MANAGEMENT

    May 1, 2003, 00:00

  • PIN16- ASSESSMENT OF ECONOMIC MODELS OF ANTIRETROVIRAL THERAPIES IN HIV/AIDS

    May 1, 2003, 00:00

  • PWM11- COST IMPLICATION OF UNRESTRICTED ACCESS TO SILDENAFIL CITRATE IN FOUR EMPLOYER GROUP PRESCRIPTION PLANS

    May 1, 2003, 00:00

  • PMH52- PATIENT-VALUED HEALTH STATE UTILITIES FOR BIPOLAR DISORDER- DIFFERENCES THAT CAN BE MEASURED

    May 1, 2003, 00:00

  • PRPI 9- BONE MINERAL DENSITY LOSS AFFECTS ESTIMATES OF THE COSTEFFECTIVENESS OF INHALED STEROIDS IN ASTHMA

    May 1, 2003, 00:00

  • PCV34- DETERMINANTS OF COST EFFECTIVENESS IN CLINICAL GUIDELINES FOR CARDIOVASCULAR PROPHYLAXIS WITH STATINS

    May 1, 2003, 00:00

  • PMD16- FACILITATING USER INTERACTION WITH PHARMACOECONOMIC MODELS- MODEL-IT

    May 1, 2003, 00:00

  • PMD29- DATABASES AND INSTRUCTION MANUALS- VALUABLE TOOLS TO BETTER LEARN ABOUT THE WHQ, PGWBI AND MLHF QUESTIONNAIRES-THE INTERNATIONAL HEALTH-RELATED QUALITY OF LIFE OUTCOMES DATABASE (IQOD) PROGRAMME

    May 1, 2003, 00:00

  • PMH32- AN ECONOMIC COMPARISON OF ANTIPSYCHOTICS IN TREATMENT OF SCHIZOPHRENIA

    May 1, 2003, 00:00

  • PES8- BURDEN OF ILLNESS OF ECZEMA IN CANADA

    May 1, 2003, 00:00

  • PMH30- A COMPARISON OF MENTAL HEALTH RESOURCES USED BY PATIENTS WITH BIPOLAR DISORDER TREATED WITH RISPERIDONE, OLANZAPINE, OR QUETIAPINE

    May 1, 2003, 00:00

  • PGS9- THE COST-EFFECTIVENESS OF HIGH DOSE ORAL VERSUS INTRAVENOUS PROTON PUMP INHIBITION IN HIGH-RISK PATIENTS WITH BLEEDING PEPTIC ULCERS HAVING UNDERGONE THERAPEUTIC ENDOSCOPY

    May 1, 2003, 00:00

  • PMH46- COST CONSEQUENCES OF APPLYING APPROPRIATE USE EDITS TO SELECT HYPNOTIC AGENTS-A RETROSPECTIVE COMPARATIVE ANALYSIS

    May 1, 2003, 00:00

  • PMH33- OLANZAPINE VERSUS RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA-A MENTAL HEALTH COST COMPARISON IN A MANAGED CARE SETTING

    May 1, 2003, 00:00

  • PES2- COST-EFFECTIVENESS OF BIMATOPROST VERSUS LATANOPROST PLUSADJUNCTIVE PRODUCTS FOR GLAUCOMA TREATMENT

    May 1, 2003, 00:00

  • PMH13- POLYPHARMACOTHERAPY OF INPATIENTS WITH SCHIZOPHRENIA

    May 1, 2003, 00:00

  • PHP56- DIRECT OBSERVATION IN INTENSIVE CARE UNITS- MEDICAL DEVICE-RELATED PROBLEMS ASSOCIATED WITH ALARMS

    May 1, 2003, 00:00

  • PIN40- THE COST EFFECTIVENESS OF IMPROVED ADHERENCE TO ANTIRETROVIRAL TREATMENT

    May 1, 2003, 00:00

  • PIN23- ECONOMIC IMPACT OF ANTIBIOTIC RESISTANCE IN THE TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA

    May 1, 2003, 00:00

  • PWM14- DEVELOPMENT OF A NEW QUALITY OF LIFE INSTRUMENT TO EVALUATE FEMALE SEXUAL DESIRE

    May 1, 2003, 00:00

  • EPI- THE IMPACT OF AN ALLERGY MANAGEMENT PROGRAM ON LOST PRODUCTIVE TIME AT WORK

    May 1, 2003, 00:00

  • PHP I 6- POLISH GUIDELINES FOR COSTING IN PHARMACOECONOMIC EVALUATION IN COMPARISON TO EXISTING GUIDANCE FOR COSTING IN OTHER COUNTRIES

    May 1, 2003, 00:00

  • PHP3I- WHAT WE HAVE MISUNDERSTOOD OF THE HIGH RATE OF OUT-OF-POCKET PAYMENTS IN HEALTH CARE SYSTEMS

    May 1, 2003, 00:00

  • PIN3- EFFECTIVENESS OF HAART IN REDUCING VIRAL LOAD (VL) AMONG A LARGE COHORT OF HIV-INFECTED PATIENTS-A SIGNIFICANT UNMET NEED

    May 1, 2003, 00:00

  • PMD21- A RELIABLE AND ROBUST ALGORITHM TO DETERMINE IN-HOSPITAL LENGTH OF STAY AND READMISSIONS USING RAMQ

    May 1, 2003, 00:00

  • PHP33- RISK SHARING IN A STATE FUNDED HEALTH SERVICE- OUTCOMES GUARANTEE PROJECT

    May 1, 2003, 00:00

  • PDB11- DETERMINATION OF ASSOCIATION BETWEEN DRUG COSTS AND MEDICAL COSTS IN PATIENTS WITH TYPE 1 DIABETES

    May 1, 2003, 00:00

  • MD4- AUTOMATING ECONOMIC ANALYSIS OF CO-MEDICATION USE IN CLINICAL TRIALS

    May 1, 2003, 00:00

  • PHP53- MORBIDITY, COMORBIDITY, PHYSICIAN COSTS AND RACE DIFFERENCES IN MORTALITY AMONG THE MEDICARE ELDERLY

    May 1, 2003, 00:00

  • PPT8- DEVELOPMENT OF THE GROWTH HORMONE INJECTION QUESTIONNAIRE (GHIQ) FOR ADOLESCENTS

    May 1, 2003, 00:00

  • PCV40- COST-EFFECTIVENESS OF RAMIPRIL IN PREVENTING CARDIOVASCULAR EVENTS IN HIGH-RISK PATIENTS

    May 1, 2003, 00:00

  • PCV9- META-ANALYSIS OF STATINS IN THE LOWERING OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL TO EUROPEAN ATHEROSCLEROSIS SOCIETY TARGET USING ROSUVASTATIN AS A COMMON COMPARATOR

    May 1, 2003, 00:00

  • PCV49- COMPARISON OF WEIGHT-RELATED SYMPTOMS AND QUALITY-OF-LIFE IMPACTS BY BODY MASS INDEX

    May 1, 2003, 00:00

  • PAR I7- COMPARING SHORT FORM AND RAND PHYSICAL AND MENTAL HEALTH SUMMARY SCORES- RESULTS FROM TOTAL HIP ARTHROPLASTYAND HIGH-RISK PRIMARY-CARE PATIENTS

    May 1, 2003, 00:00

  • PCV20- DYSLIPIDEMIA PATTERNS AMONG HIGH RISK MEMBERS OF A MANAGED CARE ORGANIZATION

    May 1, 2003, 00:00

  • PCV49- COST EFFECTIVENESS STUDY OF IMPLANTABLE CARDIOVERTER DEFIBRILLATOR VS. CONVENTIONAL TREATMENT IN PREVENTING SUDDEN DEATH AMONG PATIENTS WITH HEART FAILURE

    May 1, 2003, 00:00

  • ND2- AN ESTIMATE OF THE DIRECT COSTS OF MIGRAINE IN THE UNITED STATES USING THE MEDICAL EXPENDITURE PANEL SURVEY

    May 1, 2003, 00:00

  • PIN47- SIDE EFFECTS AND THEIR BURDEN ON HIV-INFECTED PATIENTS

    May 1, 2003, 00:00

  • PMD30- AN IMPROVED MODEL TO CALCULATE UTILITY SCORES FROM SF-36 DATA

    May 1, 2003, 00:00

  • PMD8- PATIENT SAFETY RESEARCH- A DISCUSSION OF TERMINOLOGY, PROPOSED DEFINITIONS, AND A CONCEPTUAL MODEL FOR ADVERSE EVENTS INVOLVING MEDICAL DEVICES

    May 1, 2003, 00:00

  • PCV27- THE IMPACT OF ATHEROTHROMBOTIC EVENTS ON RESOURCE USE AND COST IN PATIENTS WITH PERIPHERAL ARTERIAL DISEASE

    May 1, 2003, 00:00

  • PCV43- PREDICTING THE BURDEN OF CONGESTIVE HEART FAILURE (CHF) IN A MANAGED CARE SETTING- A NEW MODEL TO PREDICT OUTCOMES AND EVALUATE THE COST-BENEFIT OF CHF MANAGEMENT

    May 1, 2003, 00:00

  • PMH10- ETHNICITY AND SCHIZOPHRENIA MEDICATION CHOICE- HALOPERIDOL, RISPERIDONE, OR OLANZAPINE

    May 1, 2003, 00:00

  • PAR IO- A COST ANALYSIS OF CELECOXIB VERSUS DICLOFENAC PLUS OMEPRAZOLE FORTHE TREATMENT OF ARTHRITIS IN A GROUP OF HIGH-RISK CHINESE PATIENTS

    May 1, 2003, 00:00

  • PMH20- IMPACT OF A CONVERSION PROGRAM FROM SERTRALINE TO GENERIC FLUOXETINE IN A STAFF-MODEL MANAGED CARE ORGANIZATION ENHANCED BY PHYSICIAN PROFILING AND ACADEMIC DETAILING

    May 1, 2003, 00:00

  • PMD13- OPTIMIZING CLINICAL EFFECTIVENESS THROUGH ACTUARIAL MODELING IN HOSPITALS

    May 1, 2003, 00:00

  • PIN37- DOES EFFECTIVE POSTHERPETIC NEURALGIA THERAPY DECREASE THE COSTEFFECTIVENESS OF ANTIVIRALS FOR ZOSTER?

    May 1, 2003, 00:00

  • PRP2- DEVELOPMENT OF A PROSPECTIVE, NON-RANDOMIZED PATIENT REGISTRY TO MEASURE REAL-WORLD CLINICAL, ECONOMIC, AND HUMANISTIC OUTCOMES

    May 1, 2003, 00:00

  • PCH5- HEALTHCARE EXPENDITURES ASSOCIATED WITH SEVEN TUMOR TYPES OF INTEREST (TOI) USING LARGE EMPLOYERS CLAIMS DATABASE

    May 1, 2003, 00:00

  • PNP35- AGE AND GENDER-STRATIFIED DIFFERENCES IN QUALITY OF LIFE IN ELDERLY CHRONIC PAIN PATIENTS

    May 1, 2003, 00:00

  • PHP I 7- SOURCES OF VARIATION IN DRUG COSTS AMONG STATE MEDICAID PROGRAMS

    May 1, 2003, 00:00

  • PHP32- A COMPARISON OF HEALTH CARE REIMBURSEMENT STRATEGIES- HOW ARE CHILDREN WITH CHRONIC CONDITIONS ENROLLED IN STATE PROGRAMS AFFECTED?

    May 1, 2003, 00:00

  • PMD3- INSTRUMENT STRENGTH AND PERFORMANCE OF A PARAMETRIC LATENT INDEX MODEL IN ESTIMATING AVERAGE TREATMENT EFFECT (ATE)

    May 1, 2003, 00:00

  • PDB20- SIMULATING THE LONG TERM COSTEFFECTIVENESS OF A COMBINATION REGIMEN OF REPAGLINIDE PLUS ROSIGLITAZONE VS. ROSIGLITAZONE MONOTHERAPY OVER A 30-YEAR PERIOD

    May 1, 2003, 00:00

  • PES15- THE FRENCH VERSION OF THE CARDIFF ACNE DISABILITY INDEX

    May 1, 2003, 00:00

  • PCV37- BASELINE PREDICTORS OF ONE-YEAR COSTS AFTER ACUTE MYOCARDIAL INFARCTION IN THE ELDERLY

    May 1, 2003, 00:00

  • PDB17- ECONOMIC ANALYSIS OF THE USE OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS IN PATIENTS WITH DIABETES MELLITUS

    May 1, 2003, 00:00

  • PIN8- PATTERNS OF ANTIBIOTIC PRESCRIBING IN TREATING COMMUNITY-ACQUIRED PNEUMONIA OUTPATIENTS

    May 1, 2003, 00:00

  • PARI5- INITIAL VALIDATION OF THE WILLINGNESS TO PAY (WTP) TECHNIQUE FOR MEASURING HEALTH CARE PREFERENCES IN JUVENILE IDIOPATHIC ARTHRITIS (JIA)

    May 1, 2003, 00:00

  • PES5- MODEL-BASED COMPARATIVE PHARMACOECONOMIC ANALYSES OF BIMATOPROST 0.03 IN THE TREATMENT OF GLAUCOMA OR OCULAR HYPERTENSION IN ADULT PATIENTS IN AUSTRIA AND FINLAND

    May 1, 2003, 00:00

  • PMH7- A MARKOV COHORT SIMULATION ESTIMATING THE RISK OF DEVELOPING CORONARY HEART DISEASE IN PATIENTS USING ANTIPSYCHOTIC DRUGS

    May 1, 2003, 00:00

  • PMD20- SYSTEMATIC REVIEW OF ECONOMIC EVALUATION STUDIES OF MEDICAL TECHNOLOGY IN THAILAND

    May 1, 2003, 00:00

  • PCN2- DARBEPOETIN ALFA 200 MCG EVERY 2 WEEKS (Q2W) AND EPOETIN ALFA 40,000 UNITS EVERY WEEK (QW) IN CHEMOTHERAPY-INDUCED ANEMIA PATIENTS RESULT IN SIMILAR INITIAL HEMOGLOBIN OUTCOMES

    May 1, 2003, 00:00

  • PHP6- THE INFLUENCE OF SELF-EFFICACY AND COMPLIANCE IN HYPERTENSION PATIENTS, DIABETES PATIENTS AND UPPER RESPIRATORY TRACT INFECTIOUS PATIENTS WHO NEED SHORT COURSE ANTIBIOTICS AT FORT ADISORN HOSPITAL, THAIALND 2000

    May 1, 2003, 00:00
  • «
  • 161
  • 162
  • 163
  • 164
  • 165
  • 166
  • 167 (current)
  • 168
  • 169
  • 170
  • »